WANG Baolian
Education
08/2006 – 07/2009: Peking Union Medical College, PhD
08/2003 – 07/2006: Academy of Military Medical Sciences, , Master
08/1999 –07/ 2003: Shandong Medical University, Bachelor
Research experiences
2009-2016: Assistant professor, Institute of Materia Medica, CAMS & PUMC
2016-present: Associate professor, Institute of Materia Medica, CAMS & PUMC
2010-2011: Visiting scholar, Wadsworth Center, New York State Department of Health, US
Research area
-Design and accomplishment of non-clinical DMPK study in new drug development
-Early evaluation of ADME of lead compounds
-Modulation on drug metabolizing enzymes and transporter
-Pharmacokinetics of traditional Chinese medicine and natural products
-PK-PD study and modeling simulation
So far, Wang has been involved in about 6 new drug (ClassⅠ) development projects and completed multiple national grant studies as principle investigator. Moreover, he has published over 30 original research papers.
1. Simultaneous determination of a novel oxazolidinone anti-tuberculosis OTB-658 and its metabolites in monkey blood by LC-MS/MS. Journal of Chromatography B, 2021,1167: 122552
2. Comparison and identification of metabolic profiling of bicyclol in rats, dogs and humans in vitro and in vivo. European Journal of Pharmaceutical Sciences, 2020, 154: 105518.
3. Polymorphic study and pharmacokinetic evaluation of hypolipidemic candidate IMM-H007. Chinese Journal of Pharmaceuticals, 2020, 51(8): 1029-1035
4. Pharmacokinetics of IMM-H007 after oral administration in Rhesus monkey using HPLC-MS/MS analysis. Acta Pharmaceutica Sinica, 2018, 53(7): 1156-1161.
5. Prediction of a therapeutic dose for Buagafuran, a potent anxiolytic agent by physiologically based pharmacokinetic/pharmacodynamic modeling starting from pharmacokinetics in rats and human. Frontiers in Pharmacology, 2017, 8: 683. doi: 10.3389/fphar.2017.00683.
6. Pharmacokinetics, tissue distribution and elimination of three active alkaloids in rats after oral administration of the effective fraction of alkaloids from Ramulus Mori, an innovative hypoglycemic agent. Molecules, 2017, 22(10), 1616; doi:10.3390/molecules22101616
7. Simultaneous quantification of 2,3,5-tri-O- acetyl-N6-(3-hydroxylaniline)adenosine and its principal metabolites in hamster blood by LC–MS/MS and its application in pharmacokinetics study. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life. Sciences, 2016, 1022：46-53.
8. Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human. European Journal of Pharmaceutical Sciences, 2015, 77: 265-272.
9. Simultaneous quantification of curdione, furanodiene and germacrone in rabbit plasma using liquid chromatography–tandem mass spectrometry and its application to a pharmacokinetic study. Biomedical Chromatography, 2015,29（9）:1393-1398.
10. Simultaneous quantification of three active alkaloids from a traditional Chinese medicine Ramulus Mori (Sangzhi) in rat plasma using liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis，2015, 109：177-183.
11. Simultaneous determination of telmisartan and amlodipine in dog plasma by LC-MS-MS. Journal of Chromatographyic Science，2015, 53（10）：1708-1713.
12. Multifaceted interaction of the traditional Chinese medicinal herb Schisandra chinensis with cytochrome P450-mediated drug metabolism in rats. Journal of Ethnopharmacology, 2014, 155: 1473–1482.
13. Chemical-Pharmacokinetic (PK)- Pharmacodynamic (PD) Fingerprints Study of Schisandra chinensis Alcoholic Extract. Acta Pharmaceutica Sinica. 2013, 48(5): 734-740.
